Nilotinib (a BCR-ABL TKI) (5 nM) and arsenic trioxide (1 μM) in combination inhibited the proliferation but promoted the differentiation of CML cells derived from patients with blast crisis [32]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.